Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Vimian Group AB (DE:0V0)
FRANKFURT:0V0
Vimian Group AB (0V0) Stock Price & Analysis
0 Followers
0V0 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€1.71 - €3.07
Previous Close€2.89
Volume0.00
Average Volume (3M)1.12K
Market Cap
€1.52B
Enterprise Value€1.77B
Total Cash (Recent Filing)€51.18M
Total Debt (Recent Filing)€296.79M
Price to Earnings (P/E)179.5
Beta1.22
Next Earnings
Aug 15, 2024EPS Estimate
€0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.02
Shares Outstanding507,703,046
10 Day Avg. Volume100
30 Day Avg. Volume1,116
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€2.92Price Target Upside1.04% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
Vimian Group AB News
Bulls Say, Bears Say
Bulls Say
Business GrowthSpecialty Pharma and Veterinary Services saw strong organic growth, with increases of 11% and 15% respectively.
Financial CompensationVimian secured a total value of USD 26 million from the sellers of VOI, strengthening its financial position.
Legal SettlementsVimian successfully reached a third settlement agreement in its indemnification process, significantly reducing financial uncertainties for the company.
Bears Say
EarningsVimian's net sales increased by just 4%, missing consensus expectations by 3%.
Financial PerformanceAdjusted EBITA declined 8%, falling short of estimates by 8% due to smaller contributions from MedTech and increased investments in diagnostics.
Organic GrowthOrganic growth was a mere 1% at the group level, heavily impacted by a 12% decline in MedTech.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00%
Insiders
0.10% Mutual Funds
0.57% Other Institutional Investors
99.32% Public Companies and
Individual Investors
0V0 FAQ
What was Vimian Group AB’s price range in the past 12 months?
Vimian Group AB lowest stock price was €1.71 and its highest was €3.07 in the past 12 months.
What is Vimian Group AB’s market cap?
Currently, no data Available
When is Vimian Group AB’s upcoming earnings report date?
Vimian Group AB’s upcoming earnings report date is Aug 15, 2024 which is in 19 days.
How were Vimian Group AB’s earnings last quarter?
Vimian Group AB released its earnings results on May 02, 2024. The company reported €0.019 earnings per share for the quarter, missing the consensus estimate of €0.026 by -€0.007.
Is Vimian Group AB overvalued?
According to Wall Street analysts Vimian Group AB’s price is currently Undervalued.
Does Vimian Group AB pay dividends?
Vimian Group AB does not currently pay dividends.
What is Vimian Group AB’s EPS estimate?
Vimian Group AB’s EPS estimate is €0.02.
How many shares outstanding does Vimian Group AB have?
Vimian Group AB has 517,032,350 shares outstanding.
What happened to Vimian Group AB’s price movement after its last earnings report?
Vimian Group AB reported an EPS of €0.019 in its last earnings report, missing expectations of €0.026. Following the earnings report the stock price went up 1.6%.
Which hedge fund is a major shareholder of Vimian Group AB?
Currently, no hedge funds are holding shares in DE:0V0
---
Vimian Group AB Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
1.43%
Trailing 12-Months
Asset Growth
-2.50%
Trailing 12-Months
Company Description
Vimian Group AB
Vimian Group AB specializes in the areas of animal health such as specialty pharma, diagnostics, medtech, and veterinary services. It offers proprietary diagnostics, prescription and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals, with a strong position within allergy, dermatology, otology and specialised nutrition.
---
0V0 Stock 12 Month Forecast
Average Price Target
€2.92
▲(1.04% Upside)
Technical Analysis
Best Analysts Covering 0V0
1 Year
1 Year Success Rate
6/7 ratings generated profit
1 Year Average Return
+17.21%
assigned a buy rating 2 months ago
Copying Adela Dashian's trades and holding each position for 1 Year would result in 85.71% of your transactions generating a profit, with an average return of +17.21% per trade.
---